Alivus Life Sciences reported Q1 FY27 revenue of ₹640 crore, marking a 6.4% increase year-on-year. The company saw robust growth in its non-GPL business, up 26.5%, while the GPL segment experienced a decline. Gross margins improved to 60.2% and EBITDA margins reached 36.6%. Alivus has guided for 10-12% revenue growth in FY27, with a focus on expanding its API and CDMO offerings.
Alivus Life Sciences Reports Q1 FY27 Earnings
Alivus Life Sciences has announced its financial results for the first quarter of FY27, ended June 30, 2026. The company reported a total revenue from operations of ₹640 crore, representing a year-on-year growth of 6.4%.
Key Financial Highlights
The company achieved a gross profit of ₹385 crore, up 16.3% year-on-year, with gross margins expanding by 510 basis points to 60.2%. This improvement was driven by new product launches, a favorable product mix, and operational efficiencies. EBITDA for the quarter stood at ₹234 crore, a substantial increase of 29.1% year-on-year, leading to an EBITDA margin of 36.6%, up 650 basis points.
Profit After Tax (PAT) for the quarter was ₹160 crore, with PAT margins at 25%. R&D expenditure for the quarter was ₹24 crore, equivalent to 3.7% of sales.
Segment Performance
The non-GPL business demonstrated strong performance with a 26.5% year-on-year growth, fueled by successful new product launches and broad-based demand across geographies. In contrast, the GPL business saw a decline of 52.6% year-on-year in Q1 FY27, attributed to inventory rationalization.
The CDMO business recorded 3.8% year-on-year growth in the first quarter. The company anticipates this segment to gain momentum in the second half of the year with the addition of new projects.
Capital Expenditure and Outlook
Capital expenditure for the quarter was ₹85 crore. The company expects to incur approximately ₹540 crore in capex for FY27. Alivus Life Sciences continues to maintain a debt-free status and generated a strong free cash flow of ₹90 crore in the quarter.
Looking ahead, Alivus Life Sciences is guiding for revenue growth of 10% to 12% in FY27, with growth expected to be skewed towards the second half of the fiscal year. The company is confident in sustaining EBITDA margins in the range of 30% to 32%.
Strategic Focus
Key execution priorities include managing regulatory approvals for the Solapur facility, strengthening the API and Life Sciences solutions portfolio, and ensuring successful product launches. The company is also actively monitoring raw material cost volatility and implementing strategies to mitigate its impact.
Source: BSE
